The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease

Abstract

This open-label extension (SP716; NCT00599196) of a 6-month, double-blind, randomized study (SP513) investigated the safety and tolerability of rotigotine transdermal system over up to ~6 years in patients with Parkinson’s disease (PD; early-stage PD at double-blind enrollment). Eligible patients completing the 6-month study received optimal dose open-label… (More)
DOI: 10.1007/s00702-013-1001-5

Topics

5 Figures and Tables

Cite this paper

@article{Giladi2013TheSA, title={The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease}, author={Nir Giladi and Babak Boroojerdi and Erwin Surmann}, journal={Journal of Neural Transmission}, year={2013}, volume={120}, pages={1321-1329} }